All Stories

  1. The Inflammatory Side of Iatrogenic Cerebral Amyloid Angiopathy: Rethinking Therapeutic Opportunities

    Article • Brain Sciences, January 2026, MDPI AG

    FEDERICO MASSA

  2. Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The  DAME  score

    Article • Epilepsia, December 2025, Wiley

    FEDERICO MASSA

  3. MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum

    Article • Journal of Parkinson’s Disease, December 2025, SAGE Publications

    FEDERICO MASSA

  4. Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson’s disease

    Article • npj Digital Medicine, December 2025, Springer Science + Business Media

    FEDERICO MASSA

  5. Cerebrospinal fluid NPTX2 and [18F]FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer’s disease

    Article • Alzheimer s Research & Therapy, November 2025, Springer Science + Business Media

    FEDERICO MASSA

  6. Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the α-Synucleinopathy Spectrum

    Article • Neurology, November 2025, Wolters Kluwer Health

    FEDERICO MASSA

  7. Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes

    Article • Journal of the American Heart Association, October 2025, Wolters Kluwer Health

    FEDERICO MASSA

  8. Clinical Pathways for Diagnosing Neurocognitive Disorders: Insights From Process Mining a Memory Clinic Cohort

    Article • Journal of the American Medical Directors Association, October 2025, Elsevier

    FEDERICO MASSA

  9. Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses

    Article • Frontiers in Neurology, September 2025, Frontiers

    FEDERICO MASSA

  10. Longitudinal changes in [18F]FDG PET brain metabolism as a prognostic marker in autoimmune encephalitis

    Article • European Journal of Pediatrics, August 2025, Springer Science + Business Media

    FEDERICO MASSA

  11. [18F]FDG PET metabolic correlates of cerebrospinal fluid TAR DNA-binding protein 43 in prodromal Alzheimer's disease

    Article • Neurobiology of Disease, July 2025, Elsevier

    FEDERICO MASSA

  12. The compensatory effect of education as revealed by resting-state electroencephalographic alpha rhythms in patients with dementia due to Parkinson’s disease: findings from an exploratory study

    Article • GeroScience, June 2025, Springer Science + Business Media

    FEDERICO MASSA

  13. Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease

    Article • Frontiers in Aging Neuroscience, May 2025, Frontiers

    FEDERICO MASSA

  14. Clinical and metabolic profiles in behavioural frontotemporal dementia: Impact of age at onset

    Article • Cortex, April 2025, Elsevier

    FEDERICO MASSA

  15. The Many Faces of REM Sleep Behavior Disorder. Providing Evidence for a New Lexicon

    Article • European Journal of Neurology, April 2025, Wiley

    FEDERICO MASSA

  16. Abnormal electroencephalographic rhythms from quiet wakefulness to light sleep in Alzheimer’s disease patients with mild cognitive impairment

    Article • Clinical Neurophysiology, March 2025, Elsevier

    FEDERICO MASSA

  17. Resting-state electroencephalographic rhythms depend on sex in patients with dementia due to Parkinson's and Lewy Body diseases: An exploratory study

    Article • Neurobiology of Disease, March 2025, Elsevier

    FEDERICO MASSA

  18. Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies

    Article • Scientific Reports, February 2025, Springer Science + Business Media

    FEDERICO MASSA

  19. Resting-State EEG Alpha Rhythms Are Related to CSF Tau Biomarkers in Prodromal Alzheimer’s Disease

    Article • International Journal of Molecular Sciences, January 2025, MDPI AG

    FEDERICO MASSA

  20. CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study

    Article • Therapeutic Advances in Neurological Disorders, January 2025, SAGE Publications

    FEDERICO MASSA

  21. Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer’s Disease: A Review and Meta-Analysis

    Article • International Journal of Molecular Sciences, November 2024, MDPI AG

    FEDERICO MASSA

  22. Clinical and biological underpinnings of longitudinal atrophy pattern progression in Alzheimer's disease

    Article • Journal of Alzheimer’s Disease, November 2024, SAGE Publications

    FEDERICO MASSA

  23. Investigating interleukin-8 in Alzheimer's disease: A comprehensive review

    Article • Journal of Alzheimer’s Disease, November 2024, SAGE Publications

    FEDERICO MASSA

  24. Relationship between Posterior Resting-State Electroencephalographic Alpha Rhythms and Cerebrospinal Fluid Biomarkers of Neuropathology in Patients with Alzheimer’s Disease Mild Cognitive Impairment

    Article • October 2024, MDPI AG

    FEDERICO MASSA

  25. Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study

    Article • npj Parkinson s Disease, October 2024, Springer Science + Business Media

    FEDERICO MASSA

  26. Anti-LGI1 encephalitis and Langerhans cell histiocytosis: Two associated entities? A case report

    Article • Heliyon, October 2024, Elsevier

    FEDERICO MASSA

  27. Toward Quantitative Neurology: Sensors to Assess Motor Deficits in Dementia

    Article • Journal of Alzheimer’s Disease, September 2024, IOS Press

    FEDERICO MASSA, Mehrnaz Hamedani

  28. FDG-PET and ASL MRI identify largely overlapping hypermetabolic and hyperperfusion changes in limbic autoimmune encephalitis

    Article • The Quarterly Journal of Nuclear Medicine and Molecular Imaging, September 2024, Edizioni Minerva Medica

    FEDERICO MASSA

  29. Metabolic and dopaminergic correlates of intellectual enrichment in de-novo Parkinson's disease patients

    Article • The Quarterly Journal of Nuclear Medicine and Molecular Imaging, September 2024, Edizioni Minerva Medica

    FEDERICO MASSA

  30. Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer’s Disease: Clues from [18F]FDG PET Voxel-Wise Analysis

    Article • Journal of Alzheimer’s Disease, August 2024, IOS Press

    FEDERICO MASSA

  31. Clinical versus biomarker-based diagnosis of neurocognitive disorders – Authors' reply

    Article • The Lancet Neurology, August 2024, Elsevier

    FEDERICO MASSA

  32. Clinical and diagnostic implications of Alzheimer’s disease copathology in Lewy body disease

    Article • Brain, July 2024, Oxford University Press (OUP)

    FEDERICO MASSA

  33. Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer’s disease mild cognitive impairment progression at a 6-month follow-up

    Article • Neurobiology of Aging, May 2024, Elsevier

    FEDERICO MASSA

  34. Ma2 antibody‐associated limbic encephalitis: The early etiology treatment may modify the disease clinical trajectory

    Article • Epileptic Disorders, April 2024, Wiley

    FEDERICO MASSA

  35. Autoimmune encephalitis: what the radiologist needs to know

    Article • Neuroradiology, March 2024, Springer Science + Business Media

    FEDERICO MASSA

  36. Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers

    Article • European Journal of Pediatrics, March 2024, Springer Science + Business Media

    FEDERICO MASSA

  37. Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy

    Article • Annals of Neurology, March 2024, Wiley

    FEDERICO MASSA

  38. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

    Article • The Lancet Neurology, March 2024, Elsevier

    FEDERICO MASSA

  39. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review

    Article • European Journal of Pediatrics, February 2024, Springer Science + Business Media

    FEDERICO MASSA

  40. Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages

    Article • Cortex, February 2024, Elsevier

    FEDERICO MASSA

  41. Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword

    Article • Journal of Neuroimmunology, February 2024, Elsevier

    FEDERICO MASSA

  42. Alzheimer’s disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era

    Article • European Journal of Pediatrics, January 2024, Springer Science + Business Media

    FEDERICO MASSA

  43. COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome

    Article • Neurological Sciences, January 2024, Springer Science + Business Media

    FEDERICO MASSA

  44. Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease

    Article • Journal of Neurology, December 2023, Springer Science + Business Media

    FEDERICO MASSA

  45. Sex differences in brain atrophy in dementia with Lewy bodies

    Article • Alzheimer s & Dementia, December 2023, Wiley

    FEDERICO MASSA

  46. Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to Alzheimer’s disease

    Article • Cerebral Cortex, August 2023, Oxford University Press (OUP)

    FEDERICO MASSA

  47. Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases

    Article • Frontiers in Neurology, July 2023, Frontiers

    FEDERICO MASSA

  48. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease

    Article • Neurology, May 2023, Wolters Kluwer Health

    FEDERICO MASSA

  49. Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort

    Article • Neurological Sciences, May 2023, Springer Science + Business Media

    FEDERICO MASSA

  50. Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnestic Mild Cognitive Impairment

    Article • Journal of Alzheimer’s Disease, May 2023, IOS Press

    FEDERICO MASSA

  51. Right posterior hypometabolism in Pisa syndrome of Parkinson’s disease: A key to explain body schema perception deficit?

    Article • Parkinsonism & Related Disorders, May 2023, Elsevier

    FEDERICO MASSA

  52. Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson’s Disease (PD) and dementia with Lewy bodies (DLB)

    Article • European Journal of Pediatrics, December 2022, Springer Science + Business Media

    FEDERICO MASSA

  53. Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements

    Article • Physica Medica, November 2022, Elsevier

    FEDERICO MASSA

  54. Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy

    Article • Journal of Alzheimer’s Disease, October 2022, IOS Press

    FEDERICO MASSA

  55. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase

    Article • Alzheimer s & Dementia, October 2022, Wiley

    Dr Alexander Haliassos, FEDERICO MASSA

  56. Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder

    Article • Movement Disorders, October 2022, Wiley

    FEDERICO MASSA

  57. A case of Huntington disease‐like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era

    Article • Clinical Case Reports, October 2022, Wiley

    FEDERICO MASSA

  58. The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson’s Disease

    Article • Journal of Parkinson’s Disease, September 2022, IOS Press

    FEDERICO MASSA

  59. Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments

    Article • Neurological Sciences, August 2022, Springer Science + Business Media

    FEDERICO MASSA

  60. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease

    Article • Journal of Neurology Neurosurgery & Psychiatry, August 2022, BMJ

    FEDERICO MASSA

  61. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 2022, BMJ

    FEDERICO MASSA

  62. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS

    Article • Frontiers in Immunology, July 2022, Frontiers

    FEDERICO MASSA

  63. Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease

    Article • International Journal of Molecular Sciences, June 2022, MDPI AG

    FEDERICO MASSA

  64. Neurological long-COVID in the outpatient clinic: Two subtypes, two courses

    Article • Journal of the Neurological Sciences, June 2022, Elsevier

    FEDERICO MASSA

  65. The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort

    Article • Journal of Alzheimer’s Disease, May 2022, IOS Press

    FEDERICO MASSA

  66. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data

    Article • Neurobiology of Aging, May 2022, Elsevier

    FEDERICO MASSA

  67. The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer’s Disease and Frontotemporal Dementia

    Article • Biomedicines, February 2022, MDPI AG

    FEDERICO MASSA

  68. Case 4: Parkinson’s Disease with Onset as Mild Cognitive Impairment (MCI)

    Article • November 2021, Springer Science + Business Media

    FEDERICO MASSA

  69. Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer’s disease

    Article • European Journal of Pediatrics, October 2021, Springer Science + Business Media

    FEDERICO MASSA

  70. Polysomnographic correlates of sleep disturbances in de novo, drug naïve Parkinson’s Disease

    Article • Neurological Sciences, September 2021, Springer Science + Business Media

    FEDERICO MASSA

  71. Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy

    Article • Movement Disorders, September 2021, Wiley

    FEDERICO MASSA

  72. Abnormal sweating and “skin flushing” as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature

    Article • Journal of the Neurological Sciences, September 2021, Elsevier

    FEDERICO MASSA

  73. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration

    Article • Journal of Neural Transmission, August 2021, Springer Science + Business Media

    FEDERICO MASSA

  74. A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection

    Article • Journal of Neuroimmunology, August 2021, Elsevier

    FEDERICO MASSA

  75. Dopaminergic and Serotonergic Degeneration and Cortical [ 18 F ]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease

    Article • Movement Disorders, May 2021, Wiley

    FEDERICO MASSA

  76. Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection

    Article • Biomedicines, March 2021, MDPI AG

    FEDERICO MASSA

  77. FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration

    Article • Clinical Nuclear Medicine, February 2021, Wolters Kluwer Health

    FEDERICO MASSA

  78. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients

    Article • European Journal of Pediatrics, January 2021, Springer Science + Business Media

    FEDERICO MASSA

  79. Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer’s Disease (MCI-AD)

    Article • Diagnostics, January 2021, MDPI AG

    FEDERICO MASSA

  80. Sex differences in neuroimaging biomarkers in healthy subjects and dementia

    Article • January 2021, Elsevier

    FEDERICO MASSA

  81. Rapid eye movement sleep behavior disorder: A proof‐of‐concept neuroprotection study for prodromal synucleinopathies

    Article • European Journal of Neurology, December 2020, Wiley

    FEDERICO MASSA

  82. Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools

    Article • EJNMMI Research, November 2020, Springer Science + Business Media

    FEDERICO MASSA

  83. Neuroimaging Findings in Mild Cognitive Impairment

    Article • October 2020, Springer Science + Business Media

    FEDERICO MASSA

  84. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease

    Article • Cortex, September 2020, Elsevier

    FEDERICO MASSA

  85. The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease

    Article • Neurobiology of Aging, September 2020, Elsevier

    FEDERICO MASSA

  86. Utility of quantitative EEG in early Lewy body disease

    Article • Parkinsonism & Related Disorders, June 2020, Elsevier

    FEDERICO MASSA

  87. Bendamustine–rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy

    Article • Journal of the Neurological Sciences, June 2020, Elsevier

    FEDERICO MASSA

  88. Brain Aging, Cardiovascular Diseases, Mixed Dementia, and Frailty in the Oldest Old: From Brain Phenotype to Clinical Expression

    Article • Journal of Alzheimer’s Disease, May 2020, IOS Press

    FEDERICO MASSA, de fiammetta monacelli

  89. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study

    Article • European Journal of Neurology, April 2020, Wiley

    FEDERICO MASSA

  90. Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study

    Article • Journal of Alzheimer’s Disease, February 2020, IOS Press

    Dario Arnaldi, FEDERICO MASSA

  91. The fate of patients with REM sleep behavior disorder and mild cognitive impairment

    Article • Sleep Medicine, February 2020, Elsevier

    FEDERICO MASSA

  92. Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia

    Article • American Journal of Geriatric Psychiatry, December 2019, Elsevier

    FEDERICO MASSA

  93. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years

    Article • Journal of Neuroimmunology, December 2019, Elsevier

    FEDERICO MASSA

  94. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker

    Article • Journal of Alzheimer’s Disease, October 2019, IOS Press

    FEDERICO MASSA

  95. Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study

    Article • Neurological Sciences, October 2019, Springer Science + Business Media

    FEDERICO MASSA

  96. Serum neurofilament light chain rate of change in Alzheimer’s disease: potentials applications and notes of caution

    Article • Annals of Translational Medicine, July 2019, AME Publishing Company

    FEDERICO MASSA

  97. Could arterial spin labelling perfusion imaging uncover the invisible in N ‐methyl‐ d ‐aspartate receptor encephalitis?

    Article • European Journal of Neurology, May 2019, Wiley

    FEDERICO MASSA

  98. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI

    Article • Neurobiology of Aging, April 2019, Elsevier

    FEDERICO MASSA

  99. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer’s Disease

    Article • Journal of Alzheimer’s Disease, March 2019, IOS Press

    FEDERICO MASSA

  100. 18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease

    Article • January 2019, Springer Science + Business Media

    FEDERICO MASSA

  101. Increased incidence of axonal Guillain‐Barré syndrome in La Spezia area of Italy: A 13‐year follow‐up study

    Article • Journal of the Peripheral Nervous System, December 2018, Wiley

    FEDERICO MASSA

  102. N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders

    Article • Schizophrenia Research, December 2018, Elsevier

    FEDERICO MASSA

  103. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease

    Article • European Journal of Pediatrics, October 2018, Springer Science + Business Media

    FEDERICO MASSA, Professor of Clinical Psychiatry Adrian PREDA

  104. Getting the high school diploma with only one hemisphere: a case report

    Article • Neurological Sciences, August 2018, Springer Science + Business Media

    FEDERICO MASSA

  105. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)

    Article • Alzheimer s Research & Therapy, April 2018, Springer Science + Business Media

    FEDERICO MASSA

  106. Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier

    Article • Cerebellum & Ataxias, March 2018, Springer Science + Business Media

    FEDERICO MASSA

  107. Machine Learning Based Analysis of FDG-PET Image Data for the Diagnosis of Neurodegenerative Diseases

    Article • January 2018, IOS Press

    FEDERICO MASSA

  108. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers

    Article • Movement Disorders, November 2017, Wiley

    Dr Fabrizio De Carli, Dario Arnaldi, FEDERICO MASSA

  109. Clinical utility and research frontiers of neuroimaging in movement disorders

    Article • The Quarterly Journal of Nuclear Medicine and Molecular Imaging, September 2017, Edizioni Minerva Medica

    FEDERICO MASSA